GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

This study has been terminated.

( Based on futility analysis showing <30% chance of meeting primary endpoint. )

First Received: August 16, 2004 Last Updated: November 3, 2008 History of Changes

Sponsor:	Cell Genesys
Information provided by:	Cell Genesys
ClinicalTrials.gov Identifier:	NCT00089856

Purpose

The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.

Condition	Intervention	Phase
Prostate Cancer	Biological: Immunotherapy with allogeneic prostate vaccine Drug: Chemotherapy (Taxotere and prednisone)	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve

Resource links provided by NLM:

MedlinePlus related topics: Cancer Prostate Cancer

Drug Information available for: Prednisone Docetaxel

U.S. FDA Resources

Further study details as provided by Cell Genesys:

Primary Outcome Measures:

Survival [ Time Frame: 0 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Bone pain and bone related events [ Time Frame: 0 ] [ Designated as safety issue: No ]

Enrollment:	626
Study Start Date:	July 2004
Study Completion Date:	October 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
2 Standard of care - chemotherapy	Drug: Chemotherapy (Taxotere and prednisone) Chemotherapy (Taxotere and prednisone)
1: Experimental Immunotherapy	Biological: Immunotherapy with allogeneic prostate vaccine Immunotherapy with allogeneic prostate vaccine

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate
Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
Detectable metastases
Any Gleason score
ECOG performance status 0-2

Exclusion Criteria:

Prior treatment with chemotherapy
Prior Immunotherapy
Prior treatment with gene therapy
Significant cancer related pain

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089856

Show 127 Study Locations

Sponsors and Collaborators

Cell Genesys

More Information

No publications provided

Responsible Party:	Cell Genesys, Inc. ( Cell Genesys, Inc )
Study ID Numbers:	G-0029, (VITAL-1)
Study First Received:	August 16, 2004
Last Updated:	November 3, 2008
ClinicalTrials.gov Identifier:	NCT00089856 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Cell Genesys:

Prostate
Cancer
Metastatic
Hormone-refractory
GVAX
Chemotherapy

Taxotere
Docetaxel
Prednisone
Vaccine
Allogeneic cells
Advanced Prostate Cancer

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Prednisone
Antineoplastic Agents, Hormonal
Genital Neoplasms, Male
Prostatic Diseases
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Urogenital Neoplasms

Genital Diseases, Male
Glucocorticoids
Hormones
Pharmacologic Actions
Docetaxel
Neoplasms
Neoplasms by Site
Therapeutic Uses
Prostatic Neoplasms

ClinicalTrials.gov processed this record on February 08, 2010